PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7.

Colón-Ríos DA, Dow J, Krysztofiak A, Liu Y, Rogers FA, Glazer PM

Open source

DOI
10.1093/narcan/zcaf047
Published
2025 Dec
Container
NAR cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/narcan/zcaf047,
  title = {PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7.},
  author = {Colón-Ríos DA and Dow J and Krysztofiak A and Liu Y and Rogers FA and Glazer PM},
  year = {2025},
  journal = {NAR cancer},
  doi = {10.1093/narcan/zcaf047},
  url = {https://doi.org/10.1093/narcan/zcaf047}
}

RIS

TY  - JOUR
TI  - PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7.
AU  - Colón-Ríos DA
AU  - Dow J
AU  - Krysztofiak A
AU  - Liu Y
AU  - Rogers FA
AU  - Glazer PM
PY  - 2025
JO  - NAR cancer
DO  - 10.1093/narcan/zcaf047
UR  - https://doi.org/10.1093/narcan/zcaf047
ER  - 

APA

DA, C., J, D., A, K., Y, L., FA, R., & PM, G. (2025). PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7.. NAR cancer. https://doi.org/10.1093/narcan/zcaf047

Source records